Targeted therapies meet AI-driven discovery as these biotech innovators reveal sharply contrasting financials, risk factors, ...

Learn more about whether Recursion Pharmaceuticals, Inc. or Syndax Pharmaceuticals, Inc. is a better investment based on AAII ...

In late June 2026, Recursion Pharmaceuticals, Inc. was added to multiple Russell value and small-cap benchmarks, including ...

In this piece we will look at the 5 Best Penny Stocks to Invest In According to Billionaires. Please visit 12 Best Penny ...

Two stocks that have fallen out of favor and one hot stock that was one of Thursday's biggest losers were on the Ark Invest ...

That admission is what some in the field call recursive self-improvement (RSI), the point at which large language models ...

While many AIs used to assist drug discovery are provided by big tech companies at a cost, a small US and China-based techbio ...

Recursion and Exscientia, two pioneers in artificial intelligence (AI)-based drug development, have completed a business combination that they vowed will enhance their ability to carry out drug ...

An updated edition of the May 18, 2026, article. The global oncology market is evolving rapidly, fueled by rising cancer incidence, an aging population and continued scientific innovation. According ...

AI is becoming more capable, but its value still depends on the data, questions and decisions behind it. Where is it ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...